Osborn Williams & Donohoe LLC increased its holdings in Abbott Laboratories (NYSE:ABT) by 3.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,584 shares of the healthcare product maker’s stock after buying an additional 4,434 shares during the quarter. Abbott Laboratories comprises 1.3% of Osborn Williams & Donohoe LLC’s portfolio, making the stock its 15th largest holding. Osborn Williams & Donohoe LLC’s holdings in Abbott Laboratories were worth $12,916,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the stock. Regal Investment Advisors LLC lifted its position in Abbott Laboratories by 4.7% in the second quarter. Regal Investment Advisors LLC now owns 4,583 shares of the healthcare product maker’s stock worth $385,000 after purchasing an additional 205 shares during the period. Hedeker Wealth LLC lifted its position in Abbott Laboratories by 18.7% in the second quarter. Hedeker Wealth LLC now owns 45,095 shares of the healthcare product maker’s stock worth $3,792,000 after purchasing an additional 7,099 shares during the period. Northpointe Capital LLC lifted its position in Abbott Laboratories by 31.3% in the second quarter. Northpointe Capital LLC now owns 68,567 shares of the healthcare product maker’s stock worth $5,766,000 after purchasing an additional 16,365 shares during the period. Delta Asset Management LLC TN lifted its position in Abbott Laboratories by 20.8% in the second quarter. Delta Asset Management LLC TN now owns 15,656 shares of the healthcare product maker’s stock worth $1,317,000 after purchasing an additional 2,701 shares during the period. Finally, Creative Planning lifted its position in Abbott Laboratories by 8.0% in the second quarter. Creative Planning now owns 362,649 shares of the healthcare product maker’s stock worth $30,499,000 after purchasing an additional 26,854 shares during the period. 73.46% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on the company. Morgan Stanley upped their target price on Abbott Laboratories from $85.00 to $93.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 16th. Wells Fargo & Co upped their target price on Abbott Laboratories from $89.00 to $91.00 and gave the stock an “outperform” rating in a research report on Thursday, June 13th. Cowen upped their target price on Abbott Laboratories from $86.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, July 18th. Jefferies Financial Group upped their target price on Abbott Laboratories from $80.00 to $98.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. Finally, Bank of America restated a “buy” rating and issued a $81.00 target price on shares of Abbott Laboratories in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have issued a buy rating to the company’s stock. Abbott Laboratories presently has a consensus rating of “Buy” and an average target price of $85.82.
Shares of NYSE:ABT traded down $0.21 on Wednesday, reaching $84.65. 167,126 shares of the company traded hands, compared to its average volume of 5,037,156. Abbott Laboratories has a fifty-two week low of $63.07 and a fifty-two week high of $88.76. The firm has a 50 day simple moving average of $85.55. The stock has a market cap of $151.68 billion, a PE ratio of 29.29, a PEG ratio of 2.41 and a beta of 1.12. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.68 and a quick ratio of 1.20.
Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, July 17th. The healthcare product maker reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.02. Abbott Laboratories had a return on equity of 17.26% and a net margin of 9.36%. The company had revenue of $7.98 billion during the quarter, compared to the consensus estimate of $8 billion. During the same quarter in the prior year, the firm earned $0.73 EPS. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. As a group, research analysts forecast that Abbott Laboratories will post 3.24 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Monday, July 15th will be issued a $0.32 dividend. The ex-dividend date is Friday, July 12th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.51%. Abbott Laboratories’s payout ratio is currently 44.44%.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Further Reading: What is the significance of a dead cat bounce?
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.